Sermorelin
Synthetic GHRH(1-29) historically marketed as Geref. Common in US anti-aging compounding.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: GRF 1-29 · Geref
Synthetic GHRH(1-29) historically marketed as Geref. Common in US anti-aging compounding.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data8.8
- Safety maturityFollow-up depth and adverse-event signal6.9
- Mechanism confidencePathway specificity and clarity6.1
- Clinical readinessDistance to physician-prescribable use7.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation7.6
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
Growth hormone elevation
1 study- moderateThorner M, Rochiccioli P, Colle M, et al.
Sermorelin 30 mcg/kg SC at bedtime for 12 months increased growth velocity in GH-deficient children; rise in IGF-1.
Observationaln=1101996unreviewed
Growth hormone elevation
1 regimenInjection-site reactions; antibody development reported. Commercial Geref withdrawn from US market 2008.
12 months; response attenuated in some patients due to antibody formation.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
3 brands across three tiers.
Medicine
1 brandRegulator-approved finished medicines. Prescribed for specific indications, manufactured under GMP, distributed through licensed pharmacies.
Compounded (US 503A)
2 brandsPatient-specific preparations from US 503A compounding pharmacies. Require a valid prescription, not FDA-approved as finished drugs. Check the pharmacy's licence and the active ingredient's status on the FDA 503A bulks list.